Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
805K
-
Number of holders
-
7
-
Total 13F shares, excl. options
-
15.7K
-
Shares change
-
-85.3K
-
Total reported value, excl. options
-
$14.4K
-
Value change
-
-$91.6K
-
Number of buys
-
2
-
Number of sells
-
-6
-
Price
-
$0.92
Significant Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q2 2023
12 filings reported holding INM - InMed Pharmaceuticals Inc. - Common Shares, no par value as of Q2 2023.
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) has 7 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.7K shares
of 805K outstanding shares and own 1.95% of the company stock.
Largest 10 shareholders include SUSQUEHANNA INTERNATIONAL GROUP, LLP (13.7K shares), BANK OF AMERICA CORP /DE/ (1.83K shares), BlackRock Inc. (50 shares), OSAIC HOLDINGS, INC. (42 shares), AllSquare Wealth Management LLC (21 shares), Federation des caisses Desjardins du Quebec (19 shares), NATIONAL BANK OF CANADA /FI/ (12 shares), TCI Wealth Advisors, Inc. (0 shares), GABLES CAPITAL MANAGEMENT INC. (0 shares), and ADVISORY SERVICES NETWORK, LLC (0 shares).
This table shows the top 7 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.